Epidemiology of Adult Pleural Disease in the United States
Comprehensive US epidemiologic data for adult pleural disease are not available. What are the epidemiologic measures related to adult pleural disease in the United States? Retrospective cohort study using Healthcare Utilization Project databases (2007-2016). Adults (≥ 18 years of age) with malignant...
Gespeichert in:
| Veröffentlicht in: | Chest 2021-10, Vol.160 (4), p.1534-1551 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1551 |
|---|---|
| container_issue | 4 |
| container_start_page | 1534 |
| container_title | Chest |
| container_volume | 160 |
| creator | Mummadi, Srinivas R. Stoller, James K. Lopez, Rocio Kailasam, Karthik Gillespie, Colin T. Hahn, Peter Y. |
| description | Comprehensive US epidemiologic data for adult pleural disease are not available.
What are the epidemiologic measures related to adult pleural disease in the United States?
Retrospective cohort study using Healthcare Utilization Project databases (2007-2016). Adults (≥ 18 years of age) with malignant pleural mesothelioma, malignant pleural effusion, nonmalignant pleural effusion, empyema, primary and secondary spontaneous pneumothorax, iatrogenic pneumothorax, and pleural TB were studied.
In 2016, ED treat-and-discharge (T&D) visits totaled 42,215, accounting for charges of $286.7 million. In 2016, a total of 361,270 hospitalizations occurred, resulting in national costs of $10.1 billion. A total of 64,174 readmissions contributed $1.16 billion in additional national costs. Nonmalignant pleural effusion constituted 85.5% of ED T&D visits, 63.5% of hospitalizations, and 66.3% of 30-day readmissions. Contemporary sex distribution (male to female ratio) in primary spontaneous pneumothorax (2.1:1) differs from older estimates (6.2:1). Decadal analyses of annual hospitalization rates/100,000 adult population (2007 vs 2016) showed a significant (P < .001) decrease for malignant pleural mesothelioma (1.3 vs 1.09, respectively), malignant pleural effusion (33.4 vs 31.9, respectively), iatrogenic pneumothorax (17.9 vs 13.9, respectively), and pleural TB (0.20 vs 0.09, respectively) and an increase for empyema (8.1 vs 11.1, respectively) and nonmalignant pleural effusion (78.1 vs 100.1, respectively). Empyema hospitalizations have high costs per case ($38,591) and length of stay (13.8 days). The mean proportion of readmissions attributed to a pleural cause varied widely: malignant pleural mesothelioma, 49%; malignant pleural effusion, 45%; nonmalignant pleural effusion, 31%; empyema, 27%; primary spontaneous pneumothorax, 27%; secondary spontaneous pneumothorax, 27%; and iatrogenic pneumothorax, 20%. Secondary spontaneous pneumothorax had the shortest time to readmission in 2016 (10.3 days, 95% CI, 8.8-11.8 days).
Significant epidemiologic trends and changes in various pleural diseases were observed. The analysis identifies multiple opportunities for improvement in management of pleural diseases. |
| doi_str_mv | 10.1016/j.chest.2021.05.026 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_pubmed_primary_34023322</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0012369221009533</els_id><sourcerecordid>2531543191</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-38620287a848ed1018dfcf8f6ca5c3a4a33f394b2fbdd5c733e0df7a78c71da63</originalsourceid><addsrcrecordid>eNp9kM1LAzEQxYMotlb_AkH26GXXJLOfgodS6wcUFLTnkCYTm7LbrZus0P_e1FaPnoaB9-bN-xFyyWjCKMtvVolaovMJp5wlNEsoz4_IkFXAYshSOCZDShmPIa_4gJw5t6JhZ1V-SgaQUg7A-ZDcTjdWY2Pbuv3YRq2JxrqvffRaY9_JOrq3DqXDyK4jv8RovrYedfTmpUd3Tk6MrB1eHOaIzB-m75OnePby-DwZz2IFWeVjKPPwYVnIMi1Rh89LbZQpTa5kpkCmEsBAlS64WWidqQIAqTaFLEpVMC1zGJHr_d1N1372obForFNY13KNbe8Ez4CFvqxiQQp7qepa5zo0YtPZRnZbwajYQRMr8QNN7KAJmokALbiuDgH9okH95_mlFAR3ewGGml8WO-GUxbVCbTtUXujW_hvwDcXsfYc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2531543191</pqid></control><display><type>article</type><title>Epidemiology of Adult Pleural Disease in the United States</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Mummadi, Srinivas R. ; Stoller, James K. ; Lopez, Rocio ; Kailasam, Karthik ; Gillespie, Colin T. ; Hahn, Peter Y.</creator><creatorcontrib>Mummadi, Srinivas R. ; Stoller, James K. ; Lopez, Rocio ; Kailasam, Karthik ; Gillespie, Colin T. ; Hahn, Peter Y.</creatorcontrib><description>Comprehensive US epidemiologic data for adult pleural disease are not available.
What are the epidemiologic measures related to adult pleural disease in the United States?
Retrospective cohort study using Healthcare Utilization Project databases (2007-2016). Adults (≥ 18 years of age) with malignant pleural mesothelioma, malignant pleural effusion, nonmalignant pleural effusion, empyema, primary and secondary spontaneous pneumothorax, iatrogenic pneumothorax, and pleural TB were studied.
In 2016, ED treat-and-discharge (T&D) visits totaled 42,215, accounting for charges of $286.7 million. In 2016, a total of 361,270 hospitalizations occurred, resulting in national costs of $10.1 billion. A total of 64,174 readmissions contributed $1.16 billion in additional national costs. Nonmalignant pleural effusion constituted 85.5% of ED T&D visits, 63.5% of hospitalizations, and 66.3% of 30-day readmissions. Contemporary sex distribution (male to female ratio) in primary spontaneous pneumothorax (2.1:1) differs from older estimates (6.2:1). Decadal analyses of annual hospitalization rates/100,000 adult population (2007 vs 2016) showed a significant (P < .001) decrease for malignant pleural mesothelioma (1.3 vs 1.09, respectively), malignant pleural effusion (33.4 vs 31.9, respectively), iatrogenic pneumothorax (17.9 vs 13.9, respectively), and pleural TB (0.20 vs 0.09, respectively) and an increase for empyema (8.1 vs 11.1, respectively) and nonmalignant pleural effusion (78.1 vs 100.1, respectively). Empyema hospitalizations have high costs per case ($38,591) and length of stay (13.8 days). The mean proportion of readmissions attributed to a pleural cause varied widely: malignant pleural mesothelioma, 49%; malignant pleural effusion, 45%; nonmalignant pleural effusion, 31%; empyema, 27%; primary spontaneous pneumothorax, 27%; secondary spontaneous pneumothorax, 27%; and iatrogenic pneumothorax, 20%. Secondary spontaneous pneumothorax had the shortest time to readmission in 2016 (10.3 days, 95% CI, 8.8-11.8 days).
Significant epidemiologic trends and changes in various pleural diseases were observed. The analysis identifies multiple opportunities for improvement in management of pleural diseases.</description><identifier>ISSN: 0012-3692</identifier><identifier>EISSN: 1931-3543</identifier><identifier>DOI: 10.1016/j.chest.2021.05.026</identifier><identifier>PMID: 34023322</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Aged ; empyema ; Empyema - economics ; Empyema - epidemiology ; epidemiology (pulmonary) ; Female ; Health Care Coalitions ; Health Expenditures ; Hospitalization - economics ; Humans ; Incidence ; Male ; mesothelioma ; Mesothelioma, Malignant - economics ; Mesothelioma, Malignant - epidemiology ; Middle Aged ; Patient Readmission - economics ; pleural diseases ; Pleural Diseases - economics ; Pleural Diseases - epidemiology ; pleural effusion ; Pleural Effusion - economics ; Pleural Effusion - epidemiology ; Pleural Effusion, Malignant ; Pleural Neoplasms - economics ; Pleural Neoplasms - epidemiology ; pleural TB ; pneumothorax ; Pneumothorax - economics ; Pneumothorax - epidemiology ; Tuberculosis, Pleural - economics ; Tuberculosis, Pleural - epidemiology ; United States - epidemiology ; Young Adult</subject><ispartof>Chest, 2021-10, Vol.160 (4), p.1534-1551</ispartof><rights>2021 American College of Chest Physicians</rights><rights>Copyright © 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c359t-38620287a848ed1018dfcf8f6ca5c3a4a33f394b2fbdd5c733e0df7a78c71da63</citedby><cites>FETCH-LOGICAL-c359t-38620287a848ed1018dfcf8f6ca5c3a4a33f394b2fbdd5c733e0df7a78c71da63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34023322$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mummadi, Srinivas R.</creatorcontrib><creatorcontrib>Stoller, James K.</creatorcontrib><creatorcontrib>Lopez, Rocio</creatorcontrib><creatorcontrib>Kailasam, Karthik</creatorcontrib><creatorcontrib>Gillespie, Colin T.</creatorcontrib><creatorcontrib>Hahn, Peter Y.</creatorcontrib><title>Epidemiology of Adult Pleural Disease in the United States</title><title>Chest</title><addtitle>Chest</addtitle><description>Comprehensive US epidemiologic data for adult pleural disease are not available.
What are the epidemiologic measures related to adult pleural disease in the United States?
Retrospective cohort study using Healthcare Utilization Project databases (2007-2016). Adults (≥ 18 years of age) with malignant pleural mesothelioma, malignant pleural effusion, nonmalignant pleural effusion, empyema, primary and secondary spontaneous pneumothorax, iatrogenic pneumothorax, and pleural TB were studied.
In 2016, ED treat-and-discharge (T&D) visits totaled 42,215, accounting for charges of $286.7 million. In 2016, a total of 361,270 hospitalizations occurred, resulting in national costs of $10.1 billion. A total of 64,174 readmissions contributed $1.16 billion in additional national costs. Nonmalignant pleural effusion constituted 85.5% of ED T&D visits, 63.5% of hospitalizations, and 66.3% of 30-day readmissions. Contemporary sex distribution (male to female ratio) in primary spontaneous pneumothorax (2.1:1) differs from older estimates (6.2:1). Decadal analyses of annual hospitalization rates/100,000 adult population (2007 vs 2016) showed a significant (P < .001) decrease for malignant pleural mesothelioma (1.3 vs 1.09, respectively), malignant pleural effusion (33.4 vs 31.9, respectively), iatrogenic pneumothorax (17.9 vs 13.9, respectively), and pleural TB (0.20 vs 0.09, respectively) and an increase for empyema (8.1 vs 11.1, respectively) and nonmalignant pleural effusion (78.1 vs 100.1, respectively). Empyema hospitalizations have high costs per case ($38,591) and length of stay (13.8 days). The mean proportion of readmissions attributed to a pleural cause varied widely: malignant pleural mesothelioma, 49%; malignant pleural effusion, 45%; nonmalignant pleural effusion, 31%; empyema, 27%; primary spontaneous pneumothorax, 27%; secondary spontaneous pneumothorax, 27%; and iatrogenic pneumothorax, 20%. Secondary spontaneous pneumothorax had the shortest time to readmission in 2016 (10.3 days, 95% CI, 8.8-11.8 days).
Significant epidemiologic trends and changes in various pleural diseases were observed. The analysis identifies multiple opportunities for improvement in management of pleural diseases.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>empyema</subject><subject>Empyema - economics</subject><subject>Empyema - epidemiology</subject><subject>epidemiology (pulmonary)</subject><subject>Female</subject><subject>Health Care Coalitions</subject><subject>Health Expenditures</subject><subject>Hospitalization - economics</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>mesothelioma</subject><subject>Mesothelioma, Malignant - economics</subject><subject>Mesothelioma, Malignant - epidemiology</subject><subject>Middle Aged</subject><subject>Patient Readmission - economics</subject><subject>pleural diseases</subject><subject>Pleural Diseases - economics</subject><subject>Pleural Diseases - epidemiology</subject><subject>pleural effusion</subject><subject>Pleural Effusion - economics</subject><subject>Pleural Effusion - epidemiology</subject><subject>Pleural Effusion, Malignant</subject><subject>Pleural Neoplasms - economics</subject><subject>Pleural Neoplasms - epidemiology</subject><subject>pleural TB</subject><subject>pneumothorax</subject><subject>Pneumothorax - economics</subject><subject>Pneumothorax - epidemiology</subject><subject>Tuberculosis, Pleural - economics</subject><subject>Tuberculosis, Pleural - epidemiology</subject><subject>United States - epidemiology</subject><subject>Young Adult</subject><issn>0012-3692</issn><issn>1931-3543</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1LAzEQxYMotlb_AkH26GXXJLOfgodS6wcUFLTnkCYTm7LbrZus0P_e1FaPnoaB9-bN-xFyyWjCKMtvVolaovMJp5wlNEsoz4_IkFXAYshSOCZDShmPIa_4gJw5t6JhZ1V-SgaQUg7A-ZDcTjdWY2Pbuv3YRq2JxrqvffRaY9_JOrq3DqXDyK4jv8RovrYedfTmpUd3Tk6MrB1eHOaIzB-m75OnePby-DwZz2IFWeVjKPPwYVnIMi1Rh89LbZQpTa5kpkCmEsBAlS64WWidqQIAqTaFLEpVMC1zGJHr_d1N1372obForFNY13KNbe8Ez4CFvqxiQQp7qepa5zo0YtPZRnZbwajYQRMr8QNN7KAJmokALbiuDgH9okH95_mlFAR3ewGGml8WO-GUxbVCbTtUXujW_hvwDcXsfYc</recordid><startdate>202110</startdate><enddate>202110</enddate><creator>Mummadi, Srinivas R.</creator><creator>Stoller, James K.</creator><creator>Lopez, Rocio</creator><creator>Kailasam, Karthik</creator><creator>Gillespie, Colin T.</creator><creator>Hahn, Peter Y.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202110</creationdate><title>Epidemiology of Adult Pleural Disease in the United States</title><author>Mummadi, Srinivas R. ; Stoller, James K. ; Lopez, Rocio ; Kailasam, Karthik ; Gillespie, Colin T. ; Hahn, Peter Y.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-38620287a848ed1018dfcf8f6ca5c3a4a33f394b2fbdd5c733e0df7a78c71da63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>empyema</topic><topic>Empyema - economics</topic><topic>Empyema - epidemiology</topic><topic>epidemiology (pulmonary)</topic><topic>Female</topic><topic>Health Care Coalitions</topic><topic>Health Expenditures</topic><topic>Hospitalization - economics</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>mesothelioma</topic><topic>Mesothelioma, Malignant - economics</topic><topic>Mesothelioma, Malignant - epidemiology</topic><topic>Middle Aged</topic><topic>Patient Readmission - economics</topic><topic>pleural diseases</topic><topic>Pleural Diseases - economics</topic><topic>Pleural Diseases - epidemiology</topic><topic>pleural effusion</topic><topic>Pleural Effusion - economics</topic><topic>Pleural Effusion - epidemiology</topic><topic>Pleural Effusion, Malignant</topic><topic>Pleural Neoplasms - economics</topic><topic>Pleural Neoplasms - epidemiology</topic><topic>pleural TB</topic><topic>pneumothorax</topic><topic>Pneumothorax - economics</topic><topic>Pneumothorax - epidemiology</topic><topic>Tuberculosis, Pleural - economics</topic><topic>Tuberculosis, Pleural - epidemiology</topic><topic>United States - epidemiology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mummadi, Srinivas R.</creatorcontrib><creatorcontrib>Stoller, James K.</creatorcontrib><creatorcontrib>Lopez, Rocio</creatorcontrib><creatorcontrib>Kailasam, Karthik</creatorcontrib><creatorcontrib>Gillespie, Colin T.</creatorcontrib><creatorcontrib>Hahn, Peter Y.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Chest</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mummadi, Srinivas R.</au><au>Stoller, James K.</au><au>Lopez, Rocio</au><au>Kailasam, Karthik</au><au>Gillespie, Colin T.</au><au>Hahn, Peter Y.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Epidemiology of Adult Pleural Disease in the United States</atitle><jtitle>Chest</jtitle><addtitle>Chest</addtitle><date>2021-10</date><risdate>2021</risdate><volume>160</volume><issue>4</issue><spage>1534</spage><epage>1551</epage><pages>1534-1551</pages><issn>0012-3692</issn><eissn>1931-3543</eissn><abstract>Comprehensive US epidemiologic data for adult pleural disease are not available.
What are the epidemiologic measures related to adult pleural disease in the United States?
Retrospective cohort study using Healthcare Utilization Project databases (2007-2016). Adults (≥ 18 years of age) with malignant pleural mesothelioma, malignant pleural effusion, nonmalignant pleural effusion, empyema, primary and secondary spontaneous pneumothorax, iatrogenic pneumothorax, and pleural TB were studied.
In 2016, ED treat-and-discharge (T&D) visits totaled 42,215, accounting for charges of $286.7 million. In 2016, a total of 361,270 hospitalizations occurred, resulting in national costs of $10.1 billion. A total of 64,174 readmissions contributed $1.16 billion in additional national costs. Nonmalignant pleural effusion constituted 85.5% of ED T&D visits, 63.5% of hospitalizations, and 66.3% of 30-day readmissions. Contemporary sex distribution (male to female ratio) in primary spontaneous pneumothorax (2.1:1) differs from older estimates (6.2:1). Decadal analyses of annual hospitalization rates/100,000 adult population (2007 vs 2016) showed a significant (P < .001) decrease for malignant pleural mesothelioma (1.3 vs 1.09, respectively), malignant pleural effusion (33.4 vs 31.9, respectively), iatrogenic pneumothorax (17.9 vs 13.9, respectively), and pleural TB (0.20 vs 0.09, respectively) and an increase for empyema (8.1 vs 11.1, respectively) and nonmalignant pleural effusion (78.1 vs 100.1, respectively). Empyema hospitalizations have high costs per case ($38,591) and length of stay (13.8 days). The mean proportion of readmissions attributed to a pleural cause varied widely: malignant pleural mesothelioma, 49%; malignant pleural effusion, 45%; nonmalignant pleural effusion, 31%; empyema, 27%; primary spontaneous pneumothorax, 27%; secondary spontaneous pneumothorax, 27%; and iatrogenic pneumothorax, 20%. Secondary spontaneous pneumothorax had the shortest time to readmission in 2016 (10.3 days, 95% CI, 8.8-11.8 days).
Significant epidemiologic trends and changes in various pleural diseases were observed. The analysis identifies multiple opportunities for improvement in management of pleural diseases.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34023322</pmid><doi>10.1016/j.chest.2021.05.026</doi><tpages>18</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-3692 |
| ispartof | Chest, 2021-10, Vol.160 (4), p.1534-1551 |
| issn | 0012-3692 1931-3543 |
| language | eng |
| recordid | cdi_pubmed_primary_34023322 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged empyema Empyema - economics Empyema - epidemiology epidemiology (pulmonary) Female Health Care Coalitions Health Expenditures Hospitalization - economics Humans Incidence Male mesothelioma Mesothelioma, Malignant - economics Mesothelioma, Malignant - epidemiology Middle Aged Patient Readmission - economics pleural diseases Pleural Diseases - economics Pleural Diseases - epidemiology pleural effusion Pleural Effusion - economics Pleural Effusion - epidemiology Pleural Effusion, Malignant Pleural Neoplasms - economics Pleural Neoplasms - epidemiology pleural TB pneumothorax Pneumothorax - economics Pneumothorax - epidemiology Tuberculosis, Pleural - economics Tuberculosis, Pleural - epidemiology United States - epidemiology Young Adult |
| title | Epidemiology of Adult Pleural Disease in the United States |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A24%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Epidemiology%20of%20Adult%20Pleural%20Disease%20in%20the%20United%20States&rft.jtitle=Chest&rft.au=Mummadi,%20Srinivas%20R.&rft.date=2021-10&rft.volume=160&rft.issue=4&rft.spage=1534&rft.epage=1551&rft.pages=1534-1551&rft.issn=0012-3692&rft.eissn=1931-3543&rft_id=info:doi/10.1016/j.chest.2021.05.026&rft_dat=%3Cproquest_cross%3E2531543191%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2531543191&rft_id=info:pmid/34023322&rft_els_id=S0012369221009533&rfr_iscdi=true |